Neurometrix Stock Performance
| NURO Stock | USD 4.33 0.11 2.48% |
On a scale of 0 to 100, NeuroMetrix holds a performance score of 10. The company secures a Beta (Market Risk) of 1.99, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NeuroMetrix will likely underperform. Please check NeuroMetrix's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether NeuroMetrix's current price movements will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in NeuroMetrix are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, NeuroMetrix displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.67) | Five Day Return 9.73 | Year To Date Return 25.05 | Ten Year Return (99.92) | All Time Return (99.74) |
Last Split Factor 1:8 | Dividend Date 2019-11-19 | Ex Dividend Date 2007-03-28 | Last Split Date 2023-11-22 |
1 | NeuroMetrix announces review of strategic options for business growth | 02/13/2024 |
2 | StockNews.com Initiates Coverage on NeuroMetrix | 02/21/2024 |
3 | NeuroMetrix, Inc. Q4 2023 Earnings Call Transcript | 02/23/2024 |
4 | Is it Time to Dump Neurometrix Inc Stock After it Is Up 31.23 percent in a Week - InvestorsObserver | 02/28/2024 |
5 | Acquisition by Nancy Katz of 5000 shares of NeuroMetrix subject to Rule 16b-3 | 03/01/2024 |
6 | Echo Lake Capital urges Neurometrix to liquidate | 03/04/2024 |
7 | Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired | 03/12/2024 |
8 | NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy | 03/14/2024 |
9 | Disposition of 625 shares by Shai Gozani of NeuroMetrix at 4.06 subject to Rule 16b-3 | 04/01/2024 |
10 | Disposition of tradable shares by Shai Gozani of NeuroMetrix at 3.03 subject to Rule 16b-3 | 04/17/2024 |
11 | Disposition of tradable shares by Horowitz Joshua of NeuroMetrix subject to Rule 16b-3 | 04/18/2024 |
12 | NeuroMetrix appoints new board director, ends ATM facility | 04/19/2024 |
| Begin Period Cash Flow | 4.3 M |
NeuroMetrix |
NeuroMetrix Relative Risk vs. Return Landscape
If you would invest 307.00 in NeuroMetrix on January 26, 2024 and sell it today you would earn a total of 126.00 from holding NeuroMetrix or generate 41.04% return on investment over 90 days. NeuroMetrix is currently generating 0.6776% in daily expected returns and assumes 5.0598% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than NeuroMetrix, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NeuroMetrix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeuroMetrix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NeuroMetrix, and traders can use it to determine the average amount a NeuroMetrix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1339
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NURO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.06 actual daily | 44 56% of assets are more volatile |
Expected Return
| 0.68 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average NeuroMetrix is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NeuroMetrix by adding it to a well-diversified portfolio.
NeuroMetrix Fundamentals Growth
NeuroMetrix Stock prices reflect investors' perceptions of the future prospects and financial health of NeuroMetrix, and NeuroMetrix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NeuroMetrix Stock performance.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (1.11) % | ||||
| Operating Margin | (1.41) % | ||||
| Current Valuation | (8.68 M) | ||||
| Shares Outstanding | 1.99 M | ||||
| Price To Earning | 6.51 X | ||||
| Price To Book | 0.37 X | ||||
| Price To Sales | 1.26 X | ||||
| Revenue | 5.9 M | ||||
| Gross Profit | 5.75 M | ||||
| EBITDA | (7.1 M) | ||||
| Net Income | (6.53 M) | ||||
| Cash And Equivalents | 20.83 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 240.88 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.79 X | ||||
| Book Value Per Share | 13.18 X | ||||
| Cash Flow From Operations | (6.08 M) | ||||
| Earnings Per Share | (6.27) X | ||||
| Market Capitalization | 8.82 M | ||||
| Total Asset | 21.42 M | ||||
| Retained Earnings | (210.11 M) | ||||
| Working Capital | 19.61 M | ||||
| Current Asset | 10.59 M | ||||
| Current Liabilities | 3.59 M | ||||
About NeuroMetrix Performance
To evaluate NeuroMetrix Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when NeuroMetrix generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare NeuroMetrix Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand NeuroMetrix market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents NeuroMetrix's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 291.29 | 305.86 | |
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.32) | (0.34) |
Things to note about NeuroMetrix performance evaluation
Checking the ongoing alerts about NeuroMetrix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NeuroMetrix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NeuroMetrix is way too risky over 90 days horizon | |
| NeuroMetrix appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (6.53 M) with profit before overhead, payroll, taxes, and interest of 5.75 M. | |
| NeuroMetrix currently holds about 20.83 M in cash with (6.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68. | |
| NeuroMetrix has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: NeuroMetrix appoints new board director, ends ATM facility |
- Analyzing NeuroMetrix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NeuroMetrix's stock is overvalued or undervalued compared to its peers.
- Examining NeuroMetrix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NeuroMetrix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NeuroMetrix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NeuroMetrix's stock. These opinions can provide insight into NeuroMetrix's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for NeuroMetrix Stock analysis
When running NeuroMetrix's price analysis, check to measure NeuroMetrix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroMetrix is operating at the current time. Most of NeuroMetrix's value examination focuses on studying past and present price action to predict the probability of NeuroMetrix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroMetrix's price. Additionally, you may evaluate how the addition of NeuroMetrix to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is NeuroMetrix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.27) | Revenue Per Share 5.664 | Quarterly Revenue Growth (0.29) | Return On Assets (0.19) | Return On Equity (0.30) |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.